Related Experiment Videos
Ischaemic preconditioning of myocardium
1The Hatter Institute for Cardiovascular Studies, London, UK. g.baxter@ucl.ac.uk
Annals of Medicine
|August 1, 1997
Summary
Ischaemic preconditioning protects the heart muscle from damage by reducing adenosine triphosphate decline and necrosis. This protective response occurs in two phases, offering potential for new therapies against ischaemic heart disease.
Area of Science:
- Cardiology
- Cellular Biology
- Biochemistry
Background:
- Myocardium possesses an inherent capacity to adapt to sublethal ischemia, enhancing resistance to severe ischemic insults.
- This adaptive response is termed 'ischaemic preconditioning'.
Purpose of the Study:
- To investigate the mechanisms and temporal phases of myocardial protection offered by ischaemic preconditioning.
- To explore the potential clinical applications and natural occurrence of preconditioning in ischaemic syndromes.
Main Methods:
- The study reviews existing evidence on ischaemic preconditioning in human myocardium, both ex vivo and in situ.
- It examines the manifestation of protection, including slowed adenosine triphosphate decline, limited necrosis, and reduced dysrhythmia severity.
Main Results:
- Ischaemic preconditioning provides protection through two distinct temporal phases: an early phase (classic preconditioning) and a later phase (delayed preconditioning).
- Evidence suggests preconditioning can occur during procedures like angioplasty and may be involved in certain angina syndromes.
Conclusions:
- Understanding the cellular mechanisms of preconditioning is crucial for developing therapies to protect the ischaemic myocardium.
- Further research may elucidate the molecular basis of ischaemic heart disease and inform therapeutic strategies.